In keeping with these results, in a phase III clinical trial including RCC patients that received either pazopanib or placebo, high baseline serum concentration of IL-8, HGF, IL-6 and TIMP1 was significantly associated with worse prognosis, independently on the treatment arm [24]. Here, HGF is linked to renal cell carcinoma.